These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26687831)

  • 1. Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients.
    Golubovic B; Prostran M; Miljkovic B; Vucicevic K; Radivojevic D; Grabnar I
    Curr Med Chem; 2016; 23(19):1998-2011. PubMed ID: 26687831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppressive drugs in paediatric liver transplantation.
    van Mourik ID; Kelly DA
    Paediatr Drugs; 2001; 3(1):43-60. PubMed ID: 11220404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection.
    Burke GW; Ciancio C; Blomberg BB; Rosen A; Suzart K; Roth D; Kupin W; Esquenazi V; Miller J
    Transplant Proc; 2002 Aug; 34(5):1610-1. PubMed ID: 12176505
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacological surrogates of allograft outcome.
    Mahalati K; Kahan BD
    Ann Transplant; 2000; 5(2):14-23. PubMed ID: 11217202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus.
    Kovarik JM; Curtis JJ; Hricik DE; Pescovitz MD; Scantlebury V; Vasquez A
    Transplant Proc; 2006 Dec; 38(10):3456-8. PubMed ID: 17175302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus in combination with tacrolimus or mycophenolate mofetil for minimizing acute rejection risk in renal transplant recipients--a single center experience.
    El-Sabrout R; Delaney V; Qadir M; Butt F; Hanson P; Butt KM
    Transplant Proc; 2003 May; 35(3 Suppl):89S-94S. PubMed ID: 12742474
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacogenetics and immunosuppressive drugs in solid organ transplantation.
    van Gelder T; van Schaik RH; Hesselink DA
    Nat Rev Nephrol; 2014 Dec; 10(12):725-31. PubMed ID: 25247332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic Drug-Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil.
    McCrea JB; Macha S; Adedoyin A; Marshall W; Menzel K; Cho CR; Liu F; Zhao T; Levine V; Kraft WK; Yoon E; Panebianco D; Stoch SA; Iwamoto M
    J Clin Pharmacol; 2019 Oct; 59(10):1331-1339. PubMed ID: 30990905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations.
    del Mar Fernández De Gatta M; Santos-Buelga D; Domínguez-Gil A; García MJ
    Clin Pharmacokinet; 2002; 41(2):115-35. PubMed ID: 11888332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developmental pharmacogenetics of immunosuppressants in pediatric organ transplantation.
    Zhao W; Fakhoury M; Jacqz-Aigrain E
    Ther Drug Monit; 2010 Dec; 32(6):688-99. PubMed ID: 21068645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients.
    Djebli N; Rousseau A; Hoizey G; Rerolle JP; Toupance O; Le Meur Y; Marquet P
    Clin Pharmacokinet; 2006; 45(11):1135-48. PubMed ID: 17048977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High variability of drug exposure: a biopharmaceutic risk factor for chronic rejection.
    Kahan BD
    Transplant Proc; 1998 Aug; 30(5):1639-41. PubMed ID: 9723224
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive drug monitoring.
    Holt DW; Armstrong VW; Griesmacher A; Morris RG; Napoli KL; Shaw LM; ; ;
    Ther Drug Monit; 2002 Feb; 24(1):59-67. PubMed ID: 11805724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Balancing efficacy and toxicity in kidney-transplant immunosuppression.
    Leichtman AB
    N Engl J Med; 2007 Dec; 357(25):2625-7. PubMed ID: 18094383
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetics of tacrolimus-based combination therapies.
    Undre NA
    Nephrol Dial Transplant; 2003 May; 18 Suppl 1():i12-5. PubMed ID: 12738758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of pharmacogenetics of immunosuppressive drugs in organ transplantation.
    Thervet E; Anglicheau D; Legendre C; Beaune P
    Ther Drug Monit; 2008 Apr; 30(2):143-50. PubMed ID: 18367973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients.
    Lam H; Jeffery J; Sitar DS; Aoki FY
    Ther Drug Monit; 2011 Dec; 33(6):699-704. PubMed ID: 22105586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.